



February 5, 2015

Xencor to Webcast Presentations at Two Upcoming Conferences in February

MONROVIA, Calif., Feb. 5, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases and cancer, today announced that it will webcast presentations by Bassil Dahiyat, Ph.D., president and chief executive officer, at two upcoming conferences in February:

- **2015 Leerink Global Healthcare Conference**
Date: Thursday, February 12, 2015
Time: 1:25 p.m. EST
Location: New York, NY
- **RBC Capital Markets' 2015 Global Healthcare Conference**
Date: Wednesday, February 25, 2015
Time: 10:00 a.m. EST
Location: New York, NY

Live audio webcasts of both presentations will be available under "Events and Presentations" in the Investors section of the Company's website located at <http://investors.xencor.com/events.cfm>. Replays of both presentations will be posted on the Xencor website approximately one hour after each event and will be available for 30 days following the live presentations.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases and cancer. Currently, eight candidates that have been engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's internally-discovered programs include: XmAb5871, which completed a Phase 1b/2a clinical trial for the treatment of rheumatoid arthritis and is in preparation for a clinical trial in IgG4-related disease in 2015; XmAb7195 in Phase 1a development for the treatment of asthma; and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Merck, Janssen R&D LLC, Alexion, Novo Nordisk and Boehringer Ingelheim. For more information, please visit www.xencor.com.

Investor Contact:

John Kuch, Vice President Finance Xencor
Tel: 626-737-8013
jkuch@xencor.com

Corporate Communications Contact:

Jason I. Spark, Canale Communications for Xencor
Tel: 619-849-6005
jason@canalecomm.com

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/xencor-to-webcast-presentations-at-two-upcoming-conferences-in-february-300030349.html>

SOURCE Xencor, Inc.

News Provided by Acquire Media